HK Stock MarketDetailed Quotes

BAO PHARMA-B (02659)

Watchlist
  • 24.540
  • -1.020-3.99%
Market Closed May 29 16:01 CST
8.00BMarket Cap-18.27P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

BAO PHARMA-B (02659) Revenue Breakdown Overview

By Business/Source

Currency:CNY
2025/FY
Stock NameRevenueRatio
许可收入40M81.38%
Sales materials3.79M7.70%
Sale of drugs3.64M7.41%
Technical services1.73M3.51%

By Product

Currency:CNY
2025/FY
Stock NameRevenueRatio
许可收入40M81.38%
Sales materials3.79M7.70%
Sale of drugs3.64M7.41%
Technical services1.73M3.51%

By Country/Region

Currency:CNY
2025/FY
Stock NameRevenueRatio
The mainland of China49.16M100.00%

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 0.00%
Sample Name
Sample Code
 -6.41%
Sample Name
Sample Code
 -8.09%
4
PETROCHINA
00857
-9.10%
5
CNOOC
00883
-10.14%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +19.59%
Sample Name
Sample Code
 +18.95%
Sample Name
Sample Code
 +6.49%
4
Lotus Holdings
600186
+3.15%
5
China Greatwall Technology Group
000066
-0.17%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -